vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Lucas GC Ltd (LGCL). Click either name above to swap in a different company.
Lucas GC Ltd is the larger business by last-quarter revenue ($7.5M vs $3.9M, roughly 1.9× Citius Pharmaceuticals, Inc.). Lucas GC Ltd runs the higher net margin — 5.6% vs -238.2%, a 243.7% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs LGCL — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $7.5M |
| Net Profit | $-9.4M | $414.1K |
| Gross Margin | 80.0% | 33.7% |
| Operating Margin | -228.7% | 4.0% |
| Net Margin | -238.2% | 5.6% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | — |
| EPS (diluted) | $-0.38 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q2 25 | — | $7.5M | ||
| Q2 24 | — | $11.5M |
| Q4 25 | $-9.4M | — | ||
| Q2 25 | — | $414.1K | ||
| Q2 24 | — | $1.0M |
| Q4 25 | 80.0% | — | ||
| Q2 25 | — | 33.7% | ||
| Q2 24 | — | 33.5% |
| Q4 25 | -228.7% | — | ||
| Q2 25 | — | 4.0% | ||
| Q2 24 | — | 8.8% |
| Q4 25 | -238.2% | — | ||
| Q2 25 | — | 5.6% | ||
| Q2 24 | — | 8.9% |
| Q4 25 | $-0.38 | — | ||
| Q2 25 | — | $0.20 | ||
| Q2 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $606.9K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $6.3M |
| Total Assets | $140.4M | $8.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q2 25 | — | $606.9K | ||
| Q2 24 | — | $978.1K |
| Q4 25 | $80.0M | — | ||
| Q2 25 | — | $6.3M | ||
| Q2 24 | — | $5.3M |
| Q4 25 | $140.4M | — | ||
| Q2 25 | — | $8.8M | ||
| Q2 24 | — | $7.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
LGCL
| Recruitment service | $4.4M | 60% |
| Others | $2.9M | 39% |
